Therapeutic Response Statement (Sensitivity) Deprecated
This therapeutic response statement Supports the relationship that BCR::ABL1 status confers therapeutic sensitivity to Asciminib in patients with Chronic Myeloid Leukemia, BCR-ABL1+.
Health Canada approved asciminib for adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) who are newly diagnosed or who have previously received 1 or more tyrosine kinase inhibitors.
This statement is based on a regulatory approval from the Health Canada:
SCEMBLIX (asciminib tablets) is indicated for adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) who are newly diagnosed or who have previously received one or more tyrosine kinase inhibitors.
Citation
Contributions
| Date | Contributor | Description |
|---|---|---|
| 2026-09-28 | Van Allen lab | Deprecated statements when consolidating CML and CML Ph+ disease codings. |
| 2024-10-30 | Van Allen lab | Initial access of FDA approvals |